Universal Sequencing Technology was established by a group of NGS technology veterans. Universal Sequencing Technology is dedicated to the development of the most advanced, cost-effective, long-read, DNA sequencing technologies. By 2017 Universal Sequencing Technology had received a total initial seed investment of $6MM and had filed patents on two key technologies. In June of 2018 Universal Sequencing Technology successfully raised an additional $8MM from strategic partner, Amoy Diagnostics Co., Ltd.
The company’s Transposase Enzyme Linked Long-read Sequencing (TELL-Seq™) technology is a simple and scalable NGS library technology that generates barcode linked-reads for genome scale sequencing applications.
Currently, Universal Sequencing Technology has filed a total of 14 patent applications covering linked, long-read library preparation chemistry and groundbreaking 3rd generation DNA sequencing technology.